Literature DB >> 12444116

Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.

Swati Bhattacharyya1, Anjulika Chawla, Kristofer Smith, Yungui Zhou, Sohel Talib, Brian Wardwell, Morton J Cowan.   

Abstract

Although engraftment following in utero stem cell transplantation can readily be achieved, a major limitation is the low level of donor chimerism. We hypothesized that a lack of space for donor cells in the recipient marrow was one of the primary reasons for failure to achieve significant engraftment, and that donor T cells could make space in an allogeneic mismatched setting. We found that 3 x 10(5) C57BL/6 (B6) naive CD3(+) cells coinjected with B6 T cell-depleted bone marrow (TCDBM) into 14- to 15-day-old BALB/c fetuses resulted in multilineage engraftment (median, 68.3%) associated with severe graft-vs-host disease (GvHD; 62 vs 0% with TCDBM alone). When 1.5 x 10(5) CD4(+) or CD8(+) cells were used, low levels of engraftment were seen vs recipients of 1.5 x 10(5) CD3(+) cells (2.4 +/- 1.1 and 6.6 +/- 3.9 vs 20.4 +/- 10.4%, respectively). To test the hypothesis that proliferation of T cells in response to alloantigen resulted in GvHD and increased engraftment, we pretreated naive T cells with photochemical therapy (PCT) using S-59 psoralen and UVA light to prevent proliferation. GvHD was reduced (60-0%), but was also associated with a significant reduction in engrafted donor cells (53.4 +/- 4.2 to 1.7 +/- 0.5%). However, when B6 T cells were sensitized to BALB/c splenocytes, treated with PCT, and coinjected with TCDBM, there was a partial restoration of engraftment (13.3 +/- 2.4% H2Kb(+) cells) with only one of nine animals developing mild to moderate GvHD. In this study we have shown that PCT-treated T cells that are cytotoxic but nonproliferative can provide an engraftment advantage to donor cells, presumably by destroying host hemopoietic cells without causing GvHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444116     DOI: 10.4049/jimmunol.169.11.6133

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation.

Authors:  Catherine T Jordan; John D Roback
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  T cell and B Cell immunity can be reconstituted with mismatched hematopoietic stem cell transplantation without alkylator therapy in artemis-deficient mice using anti-natural killer cell antibody and photochemically treated sensitized donor T cells.

Authors:  Tony Z Xiao; Kanal Singh; Elizabeth Dunn; Rageshree Ramachandran; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-19       Impact factor: 5.742

3.  Radiosensitive severe combined immunodeficiency disease.

Authors:  Christopher C Dvorak; Morton J Cowan
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

4.  Prevention of graft rejection by donor type II CD8(+) T cells (Tc2 cells) is not sufficient to improve engraftment in fetal transplantation.

Authors:  Jeng-Chang Chen; Ming-Ling Chang; Hanmin Lee; Marcus O Muench
Journal:  Fetal Diagn Ther       Date:  2005 Jan-Feb       Impact factor: 2.587

Review 5.  Immunological Consequences of In Utero Exposure to Foreign Antigens.

Authors:  Jeng-Chang Chen
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 6.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

7.  In Utero Exposure to Exosomal and B-Cell Alloantigens Lessens Alloreactivity of Recipients' Lymphocytes Rather than Confers Allograft Tolerance.

Authors:  Jeng-Chang Chen; Liang-Shiou Ou; Cheng-Chi Chan; Ming-Ling Kuo; Li-Yun Tseng; Hsueh-Ling Chang
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.